Key points are not available for this paper at this time.
This Viewpoint discusses the optimal treatment duration of glucagon-like peptide-1 receptor agonists in people with obesity and the benefits of off-ramping, the tapering of these antiobesity medications following an initial treatment period.
Manne‐Goehler et al. (Mon,) studied this question.